Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 13 of 13 entries
View as:

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

Phase: N/A Priority: Normal
NCT ID: NCT04735536 Org: User:
Start: 07/09/20 End: 04/26/23 Due: 04/26/24

Ascending Dose Study of CT1812 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02570997 Org: User:
Start: 09/30/15 End: - Due: -

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Phase: N/A Priority: Normal
NCT ID: NCT05893537 Org: User:
Start: 06/16/23 End: 03/28/25 Due: 03/28/26

Effect of CT1812 Treatment on Brain Synaptic Density

Phase: N/A Priority: Normal
NCT ID: NCT03493282 Org: User:
Start: 03/28/18 End: 10/16/20 Due: 10/16/21

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05531656 Org: User:
Start: 06/28/23 End: 04/30/27 Due: 04/30/28

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05248672 Org: User:
Start: 02/15/22 End: 06/01/22 Due: 06/01/23

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03522129 Org: User:
Start: 05/30/18 End: 02/06/19 Due: 02/06/20

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Phase: N/A Priority: Normal
NCT ID: NCT05225415 Org: User:
Start: 05/19/22 End: 11/25/24 Due: 11/25/25

Drug Interaction Study of CT1812 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03716427 Org: User:
Start: 11/10/16 End: 02/15/17 Due: 02/15/18

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05225389 Org: User:
Start: 12/31/21 End: 01/24/22 Due: 01/24/23

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02907567 Org: User:
Start: 09/30/16 End: 09/30/17 Due: 09/30/18

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Phase: N/A Priority: Normal
NCT ID: NCT03507790 Org: User:
Start: 10/10/18 End: 05/29/24 Due: 05/29/25

Expanded Access Program for CT1812 (Zervimesine)

Phase: N/A Priority: Normal
NCT ID: NCT06961760 Org: User:
Start: - End: - Due: -